Sialis 5 mg 14 tablets
Tamiflu 75 mg 10 capsules
Hypoxen 250 mg 30 capsules
Semax nasal drops 0.1% 3 ml
Sildenafil 100 mg 20 tablets
Ovestin 2 mg 30 tablets
Ovestin Vaginal cream 15g
Ventolin nebula 20 ampoules
Avodart 0,5 mg 90 capsules
Avodart 0,5 mg 30 capsules
- Antibacterial medication
- Antifungal medication
- Antiviral Medication
- Cardiovascular medication
- different medication
- Hormonal medication
- Immunosuppressants and immunomodulating medications
- Nervous system
- Pain relievers and anti-inflammatory
- Respiratory system
- Treatment of diseases of the liver and gastrointestinal tract
- Treatment of sensory organs, eyesight and hearing
- Urogenital system
De-Nol 120mg 112 tablets
De-Nol 120mg 56 tablets
De-Nol 120mg 32 tablets
finasteride 5mg 30 tablets
Itrazole 100 mg 42 capsules
furasol 15 sachets of 100 mg
Triacort OINTMENT 0.1% 10G
Urseptia 200 mg 20 capsules
Minolexin 100 mg 20 capsules
Immard 200 mg 30 tablets
Adenuric 120 mg 28 tablets
Champix 1 mg 112 tablets
Ingavirin 90 mg 10 capsues
Vestibo 16 mg 30 tablets
Betahistine 16 mg 30 tablets
Cinnarizine 25 mg 50 tablets
Novo-passit 60 tablets
Ceraxon 500 mg/4 ml 5 vials
Picamilon 50 mg 30 tablets
Ginos 40 mg 30 tablets
Cortexin 10 mg 10 vials
Mirapex 1 mg 30 tablets
Cerebrolysin 5 ml 5 vials
Betahistine 24 mg 60 tablets
Stugeron 25mg 50 tablets
Baclosan 10 mg 50 tablets
Magnelis B6 90 tablets
Mirapex 1.5 mg 30 tablets
Mydocalm 1 ml 5 vials
Mexidol 125 mg 30 tablets
Biloba 40 mg 60 capsules
Persen night 20 capsules
Persen 60 tablets
Selank 0.15% nasal drops
Agalates 0,5 mg 8 Tablets
Manufacturer: AYVEKS Pharmaceuticals sro
Country of Origin: Czech Republic
General description: inhibitor of prolactin secretion
Dosage form
Pills
Composition
cabergoline 500 mcg
Auxiliary substances: lactose, L-leucine, magnesium stearate (Е572).
Pharmacological action
Dopamine receptor agonist. Cabergoline is a synthetic ergot alkaloid that is derived Ergoline, dopamine agonist with prolonged action, inhibiting the secretion of prolactin. The mechanism of action of cabergoline involves the stimulation of Central dopamine receptors of the hypothalamus. At doses higher than required to suppress the secretion of prolactin, the drug causes Central dopaminergic effect, due to stimulation of dopamine D2-receptors. The effect of the drug is dose dependent in nature. Decreasing the amount of prolactin in blood is usually observed after 3 h and persists for 2-3 weeks, in connection with than to suppress the secretion of milk is usually enough of a single dose of the drug. In the treatment of hyperprolactinemia prolactin content in normal blood after 2-4 weeks of using the drug in an effective dose. Normal levels of prolactin can persist for months after discontinuation of the drug.
Cabergoline has a highly selective effect and no effect on basal secretion of other pituitary hormones and cortisol. The only pharmacodynamic effect linked to therapeutic effect is a decrease in blood pressure. The maximum hypotensive effect usually develops within 6 h after a single dose of the drug; the degree of blood pressure reduction and incidence of hypotensive effect dose-dependent.
Contraindications
postpartum or uncontrolled hypertension;
— severe disturbances of liver function;
— adverse events from the lungs such as pleuritis or fibrosis (including in history), associated with the use of dopamine agonists;
— psychosis (W. in history) or the risk of development;
— pregnancy and developed on the background of preeclampsia and eclampsia;
— lactation (breastfeeding);
— hypersensitivity to cabergoline, other ergot alkaloids or any component of the drug.
The efficacy and safety of the use of cabergoline in children under 16 years of age have not been studied.
With caution should appoint drug patients with cardiovascular disease, hypotension, Raynaud's syndrome, peptic ulcers or gastrointestinal bleeding, patients with end-stage renal failure or on hemodialysis, elderly patients
Drug interactions
Influence of macrolide antibiotics on the plasma of cabergoline in combination has not been studied. Given the possibility of increasing the level of cabergoline, the drug is not recommended for use in combination with macrolides.
The mechanism of action of cabergoline is associated with direct stimulation of dopamine receptors, so it should not be used in combination with antagonists of dopamine receptors (phenothiazines, butyrophenone, thioxanthene, metoclopramide).
There is no information on interactions of cabergoline with other ergot alkaloids, however, we do not recommend prolonged use of this combination.
Given the pharmacodynamics of cabergoline (hypotensive effect), it is necessary to take into account the interaction with drugs that reduce blood pressure.
In clinical studies in patients with Parkinson's disease pharmacokinetic interaction with levodopa or selegiline was not detected.


.